financetom
Business
financetom
/
Business
/
Biocon Q3FY21: Here's what to expect
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Biocon Q3FY21: Here's what to expect
Jan 20, 2021 7:49 AM

Stock of pharma major Biocon has risen 60 percent from its March 2020 lows. The company is scheduled to report its Q3FY21 earnings tomorrow (January 21).

CNBC-TV18 poll suggest a revenue growth of 10 percent and margins are expected to come at around 25 percent.

Watch video for more.

(Edited by : Bivekananda Biswas)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Southwest Airlines begins flying first plane with secondary cockpit barrier
Southwest Airlines begins flying first plane with secondary cockpit barrier
Aug 29, 2025
Aug 29 (Reuters) - Southwest Airlines ( LUV ) began Friday flying its first jet with a secondary barrier to the flight deck designed to prevent intrusions. The plane - a Boeing 737 MAX 8 which was delivered in recent days - took off Friday afternoon from Phoenix to Denver, the airline said. Secondary barriers -- long sought after the...
Corby Spirit and Wine to Represent Certain Vinarchy Wines in Canada Starting September
Corby Spirit and Wine to Represent Certain Vinarchy Wines in Canada Starting September
Aug 29, 2025
05:02 PM EDT, 08/29/2025 (MT Newswires) -- Canada's Corby Spirit and Wine (CSW-A.TO) and global wine company Vinarchy after trade Friday said they have entered into a two-year deal, starting Sept. 1, 2025, that gives Corby exclusive rights to represent certain Vinarchy wine brands in Canada. Under an agreement, Corby will continue to represent well-known former Pernod Ricard Winemakers' brands...
US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug
US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug
Aug 29, 2025
By Mariam Sunny Aug 29 (Reuters) - The U.S. Food and Drug Administration has approved an injectable version of Eisai ( ESALF ) and Biogen's Alzheimer's disease drug Leqembi, the companies said on Friday, allowing for an easier treatment option following an initial intravenous infusion. The approval makes Leqembi the first Alzheimer's treatment that can be administered at home as...
Calix Insider Sold Shares Worth $600,000, According to a Recent SEC Filing
Calix Insider Sold Shares Worth $600,000, According to a Recent SEC Filing
Aug 29, 2025
05:02 PM EDT, 08/29/2025 (MT Newswires) -- Cory Sindelar, Chief Financial Officer, on August 28, 2025, sold 10,000 shares in Calix (CALX) for $600,000. Following the Form 4 filing with the SEC, Sindelar has control over a total of 76,555 common shares of the company, with 76,555 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1406666/000122686825000007/xslF345X05/wk-form4_1756501026.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved